LI-RADS Version 2018 for MRI and CT: Interreader Agreement in Real-World Practice.

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

Who cites it

4 citing papers in PubMed.

1. MRI radiomics combined with clinical factors to predict vessels encapsulating tumor clusters and early recurrence in hepatocellular carcinoma (≤ 3 cm).BMC medical imaging · 2026
   Article
2. Concurrent AI assistance with LI-RADS classification for contrast enhanced MRI of focal hepatic nodules: a multi-reader, multi-case study.Abdominal radiology (New York) · 2026
   Article
3. MRI-based prediction of the need for wide resection margins in patients with single hepatocellular carcinoma.European radiology · 2025
   Article
4. Nomogram prediction of vessels encapsulating tumor clusters in small hepatocellular carcinoma ≤ 3 cm based on enhanced magnetic resonance imaging.World journal of gastrointestinal oncology · 2024
   Article

Corrections and comments

• Comment on
  A Multicenter Assessment of Interreader Reliability of LI-RADS Version 2018 for MRI and CT.2023

Authors and funding

2 authors.

Funding

No grant is acknowledged in the PubMed record.

Abstract

PubMed holds no abstract for this paper.

Indexed as